Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Voclosporin in adolescent and pediatric lupus nephritis (VOCAL-EXT)
NCT05962788Phase 3Terminated
- Sponsor
- Aurinia
- Start
- Mar 2024
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, open-label, single-arm trial of voclosporin in lupus nephritis (LN), sponsored by Aurinia. Primary endpoint: Treatment Emergent Adverse Events at 12 months. Started Mar 2024; status: terminated.
02
Drugs
voclosporin
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on NCT05962788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05962788.